Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia

Abstract Background Heterozygous loss-of-function mutations in the progranulin (PGRN) gene (GRN) cause a reduction in PGRN and lead to the development of frontotemporal dementia (FTD-GRN). PGRN is a secreted lysosomal chaperone, immune regulator, and neuronal survival factor that is shuttled to the...

Full description

Bibliographic Details
Main Authors: Michael Kurnellas, Ananya Mitra, Tina Schwabe, Robert Paul, Andrew E. Arrant, Erik D. Roberson, Michael Ward, Felix Yeh, Hua Long, Arnon Rosenthal
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Journal of Translational Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12967-023-04251-y